1H-Pyrrolo[3,2-c]pyridin-4(5H)-one, 95.0%, 100mg

1-Fluorocyclohexanecarboxylic acid, 97.0%, 250mg

4'-(tert-Butyl)-[1,1'-biphenyl]-4-carboxylic acid, 95.0%, 25g

4-(Bromomethyl)pyrimidine hydrobromide, 95.0%, 1g

3-Oxetanone>97.0%(GC)1g

2-Amino-1-(3-fluorophenyl)ethanol, 95.0%, 500mg

GC-Kapillarsäule ROTI®Cap-1701 MS, L 60 m, Ø-Innen 0,25 mm, Filmd. 0,25 µm, 1 Stück

6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide, 99+%, 250mg

7-Chloroquinoline-3-carboxylic acid, 95.0%, 1g

2-Bromo-3-hydroxybenzonitrile, 95.0%, 1g

O-((Perfluorophenyl)methyl)hydroxylamine hydrochloride, 95.0%, 25g

Ethyl 3-(4-fluorophenyl)-1H-pyrazole-5-carboxylate, 95.0%, 2g

4-(BOC-AMINO)-N-FMOC-D-PHENYLALANINE, 95%, 25g